Free Health Updates
Skip to main content
Table of Contents
< All Topics
Print

Has NICE Issued Guidelines for Cannabis in Depression? 

Posted
Updated
ByMy Patient Advice
Author: Dr. Clarissa Morton, PharmD

The current position on NICE cannabis and depression guidelines is one of caution. As it stands, NICE has not recommended cannabis-based medicines for the routine treatment of depression . While there is growing public interest, the body highlights that more research is needed before such therapies can be formally included in recognised clinical guidelines. 

NICE has focused much of its advice on cannabis use in chronic pain, epilepsy, and multiple sclerosis but has stopped short of supporting its use in mental health. This reflects the lack of large-scale trials that demonstrate consistent benefits for depression. 

Is Medical Cannabis Legal in UK?

How It May Help 

Though NICE cannabis and depression guidelines remain absent, other forms of UK guidance and research reviews provide useful insight. These show that cannabinoids like CBD may influence mood regulation and sleep, but evidence is currently considered too limited for official recommendation. Below are some of the main considerations raised in discussions around cannabis and depression. 

UK Guidance 

Broader UK guidance stresses the need for careful prescribing and further study. While patients often report benefits, regulators highlight that clinical data is still sparse. 

Clinical Guidelines 

Within existing clinical guidelines, cannabis is currently mentioned in relation to specific physical health conditions, not mental health. This means depression treatments continue to rely on established approaches like talking therapies and antidepressant medication. 

Regulatory Advice 

Regulators emphasise that any expansion of cannabis-based treatments must be supported by stronger trials. Current regulatory advice prioritises safety, standardised dosing, and close monitoring where cannabis is prescribed for other conditions. 

In summary, NICE cannabis and depression guidelines are not yet in place, reflecting a cautious stance rooted in limited evidence. This highlights the importance of ongoing research to establish clearer answers for patients and clinicians alike. 

For those seeking professional insight into whether medical cannabis could be appropriate, providers like LeafEase can offer confidential consultations tailored to individual needs. 

For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Medical Cannabis and Depression.

Dr. Clarissa Morton, PharmD
Author

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Categories